Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …

Most patients treated with US Food and Drug Administration (FDA)–approved chimeric
antigen receptor (CAR) T cells eventually experience disease progression. Furthermore …

T cells are fundamental components in tumour immunity and cancer immunotherapies,
which have made immense strides and revolutionized cancer treatment paradigm. However …

Background The paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell
therapy of solid tumors necessitates careful preclinical evaluation of the therapeutic window …

Malignant tumors of the hematologic system have a high degree of malignancy and high
mortality rates. Chimeric antigen receptor T cell (CAR-T) therapy has become an important …

Mesothelin is a glypiated, cell-surface glycoprotein expressed at low levels on normal
mesothelium but overexpressed by many cancers. Implicated in cell adhesion and multiple …

Purpose: The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is expressed in
hematopoietic and epithelial cancers but has limited expression on normal adult tissues …

Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment for
hematological malignancies, but its adaptation to solid tumors is impeded by multiple …

Chimeric antigen receptor (CAR) T cells express antigen-specific synthetic receptors, which
upon binding to cancer cells, elicit T cell anti-tumor responses. CAR T cell therapy has …